Posts tagged MRSA
Roth upgrades Cempra to buy

Roth Capital Partners upgraded Cempra (NASDAQ:CEMP) to “buy” and maintained its $8 price target after the company announced positive Phase 3 results in the first of two skin infection (ABSSSI) studies with Taksta. The stock was quoted at $4.20 near midday on Feb. 27.

Read More
Wainwright starts Nabriva Therapeutics at buy

H.C. Wainwright initiated coverage of Nabriva Therapeutics (NASDAQ:NBRV) with a “buy” rating and $16 price target. The stock closed at $7.92 on Wednesday.

Originally spun-off from Sandoz, Austria-based Nabriva has in-house expertise and broad, wholly-owned IP protection in the development of a novel pleuromutilin class of antibiotics.

Read More
Dipexium Pharma receives Locilex patent in Japan

Dipexium Pharmaceuticals (NASDAQ:DPRX) has received a patent in Japan, covering a novel formulation of Locilex, an antimicrobial peptide formulated as a topical cream. The issued patent has an expiry date in June 2033.

“We are delighted to receive a Locilex patent in Japan, the third largest pharmaceuticals market in the world,” David Luci, president and CEO, said in a statement.

Read More
HCW starts Paratek Pharma at buy

H.C. Wainwright has initiated coverage of Paratek Pharmaceuticals (NASDAQ:PRTK) with a “buy” rating and $32 price target. The stock closed at $15.51 on Friday.

Paratek’s lead drug, omadacycline, is a broad-spectrum antibiotic with potent coverage of common bacterial pathogens such as MRSA in both acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP); multi-drug resistant Streptococcus pneumoniae (MDRSP) in CABP; and extended spectrum beta-lactamase-producing Enterobacteriaceae in urinary tract infections (UTI).

Read More